AVLN — Avalyn Pharma Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1540171 ·
Last close
$27.92
Market Cap
$1.24B
52W High
$40.17
52W Low
$22.24
ADV30
443,247
Next earnings
2026-11-12
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -33,094,000 -29,655,000 399,296,000 145,424,000 29,046,000
Jun 2026 0 — -31,290,000 -28,935,000 425,448,000 264,197,000 27,102,000
Mar 2026 0 — -27,909,000 -26,869,000 135,663,000 92,310,000 399,908,000
Dec 2025 0 — -25,476,000 -23,926,000 148,881,000 52,315,000 387,537,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-95,939,000
Investing CF
$-76,252,000
Financing CF
$421,419,000
CapEx
$-595,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.20
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-321,167,000
Inventory
—
Receivables
$1,674,000
ST Investments
$88,228,000
EBIT TTM
$-93,128,000
Pretax Income TTM
$-93,498,000
Interest Exp TTM
$370,000
Analysts
5

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -91,292,000 -85,204,000 148,881,000 387,537,000 -238,656,000 -81,484,000
Dec 2024 0 -57,121,000 -49,744,000 124,519,000 299,041,000 -174,522,000 -48,368,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$425,448,000
Forward EPS
$-2.58

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $40.00 · spot: $27.69 · call volume: 0 · put volume: 26

Peers — same industry

TickerNameMarket CapLastDaily %
AMPH Amphastar Pharmaceuticals, Inc. $1.24B $29.10 —
KARD Kardigan, Inc. $1.23B $13.19 —
GHRS GH Research PLC $1.25B $18.27 —
SLN Silence Therapeutics plc $1.23B $19.80 —
AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL $1.23B $13.14 —

News headlines (Yahoo Finance, 1h cache)

Avalyn: Q3 Earnings Snapshot
2026-11-12 13:26 · Yahoo
Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-12 13:00 · Yahoo
Avalyn to Present at Upcoming Investor Conferences
2026-11-03 13:00 · Yahoo
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
2026-09-16 20:01 · Yahoo
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
2026-09-08 12:00 · Yahoo
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
2026-08-24 20:01 · Yahoo
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-12 12:00 · Yahoo
Avalyn to Participate in the Jefferies Global Healthcare Conference
2026-05-27 12:00 · Yahoo
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
2026-06-06 02:06 · Yahoo
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-06-03 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.